O T C
PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

  Sandusky, OH, January 14, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year.  The strategic outlook is included in its entirety below: PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook PAOG is

PAOG Dividend Update Included In 2021 Cannabis Biopharmaceutical Strategic Update Tomorrow

  Sandusky, OH, January 13, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the upcoming update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook scheduled for tomorrow, Thursday Jan 14th, 2021, will include an update on the planned PAOG stock dividend to shareholders of Puration, Inc. (OTC

PAOG Confirms Q4 2020 Revenue From Cannabis Asset Acquisition

  Sandusky, OH, January 8, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today confirmed that the company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA)

PAOG Takes Major CBD Pharmaceutical Development Step Forward

  Sandusky, OH, January 5, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product. PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts.  PAOG has engaged Veristat to assist in advancing

PAOG Publishes First Financial Report Following Two Strategic Acquisitions

Dallas, Texas, November 17, 2020 – OTC PR WIRE – PAO Group, Inc. (OTC US: PAOG) today announced publishing its Q3 2020 report with OTC Markets. This is the first report since making two strategic acquisitions in the course of the third quarter. PAOG transitioned its business direction in the previous quarter making the acquisition

PURA CEO Interviewed About His Plan For $26 Billion Hemp Market By CEO Roadshow

Dallas, Texas, November 16, 2020 – Puration, Inc. (OTC US: PURA) today announced the release of an interview of CEO Brian Shibley conducted by CEO Roadshow in association with OTC PR Wire (www.otcprwire.com) – the #1 solution for press, financial disclosure and multimedia solutions for companies trading in the OTC Market. In the interview, Mr.

PAOG Building CBD Pharma Capacity In Partnership With PURA – Partnership Includes PAOG Stock Dividend To PURA Shareholders

Sandusky, Ohio – November 12, 2020 – OTC PR WIRE – PAO Group, Inc. (OTC PINK: PAOG) today confirmed a pharmaceutical and neurocritical extraction partnership with Puration, Inc. (OTC PINK: PURA). PURA has acquired a 72-acre property in Farmersville, Texas as the foundation of an innovative, hemp processing plant. PURA is building partnerships to participate

PURA 72 Acre Hemp Processing Plant Coming To Texas With PAOG and ALKM

Dallas, Texas, November 11, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today confirmed the company has acquired a 72-acre property in Farmersville, Texas as the foundation of an innovative, hemp processing plant. PURA is building partnerships to participate in the project to include a pharmaceutical and neurocritical extraction partnership with PAO

PURA 1 For 1 Shareholder Dividend of PAOG Shares On Track

Dallas, TX – October 30, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) and Puration, Inc. (OTC PINK: PURA) today released an update on the process underway for PAOG to issue PAOG shares to PURA shareholders in a dividend distribution. PAOG acquired a cannabis cultivation operation from PURA earlier this year

PAOG Advances Nutraceutical Development From Its Cannabis Pharmaceutical Research

Sandusky, OH, October 29, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced adding a nutraceutical development pathway to its existing pharmaceutical cannabis drug development strategy.  Last week, PAOG announced a master services agreement with a clinical research organization (CRO) in the U.S. to prepare PAOG for initiating an investigational

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019